Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma

Shigetaka Suekane,1,2 Kousuke Ueda,1 Kiyoko Nishihara,1 Tetsuro Sasada,2 Takuto Yamashita,4 Noriko Koga,3 Shigeru Yutani,2 Shigeki Shichijo,2 Kyogo Itoh,2 Tsukasa Igawa1 and Masanori Noguchi1,2,5

1Department of Urology, Kurume University School of Medicine; 2Kurume University Cancer Vaccine Center, Kurume; 3Kanagawa Cancer Center, Yokohama; 4Biostatics Center; 5Division of Clinical Research, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan

Key words
Cancer vaccine, immunotherapy, personalized medicine, phase II trial, upper tract urothelial cancer

Correspondence
Shigetaka Suekane, Department of Urology, Kurume University School of Medicine, 67 Asahimachi, Kurume 830-0011, Japan. Tel: +81-942-31-7572; Fax: +81-942-34-2605; E-mail: suekane@med.kurume-u.ac.jp

Funding Information
Japan Society for the Promotion of Science (JP15K10614); Japan Agency for Medical Research and Development; Ministry of Education, Culture, Sports, Science and Technology of Japan; Sendai Kosei Hospital, Japan

Received June 8, 2017; Revised September 6, 2017; Accepted September 15, 2017

Cancer Sci 108 (2017) 2430–2437
doi: 10.1111/cas.13404

This study investigated the applicability of personalized peptide vaccination (PPV) for patients with metastatic upper tract urothelial cancer (mUTUC) after failure of platinum-based chemotherapy. In this single arm, open-label, phase II clinical trial, patients with mUTUC received PPV at a single institution. Personalized peptide vaccination treatment used a maximum of four peptides chosen from 27 candidate peptides according to human leukocyte antigen types and peptide-reactive IgG titers, for six s.c. injections weekly as one cycle. The safety of PPV, as well as its influence on host immunity and effect on overall survival were assessed. Forty-eight patients were enrolled in this study. Personalized peptide vaccinations were well tolerated without severe adverse events. Median survival time was 7.3 months (95% confidence interval [CI], 5.3–13.1) with 13.0 months for patients receiving combined salvage chemotherapy (95% CI, 5.7–17.5) and 4.5 months for patients receiving PPV alone (95% CI, 1.7–10.1) (P = 0.080). Patients with positive CTL responses showed a significantly longer survival than patients with negative CTL responses (hazard ratio, 0.37; 95% CI, 0.16–0.85; P = 0.019). Multivariate Cox regression analysis showed that lower numbers of Bellmunt risk factors and lower levels of B-cell activating factor were significantly associated with favorable overall survival for patients under PPV treatment. This study indicated that PPV for patients with mUTUC after failure of platinum-based chemotherapy induced substantial peptide-specific CTL responses without severe adverse events and has the potential to prolong survival when combined with salvage chemotherapy. UMIN Clinical Trials Registry ID: 00001854.

Upper tract urothelial carcinomas (UTUCs) are relatively uncommon compared to bladder cancer, accounting for only 5–10% of urothelial cancers (UC), and are aggressive urological cancers with a propensity for multilocality, local recurrence, and metastasis.1–3 Upper tract urothelial carcinomas have a peak incidence in people aged 70–90 years, and 60% of UTUCs are invasive at diagnosis.1–3 For advanced or metastatic disease, chemotherapy would be the main choice.4,5 Although there are currently insufficient data recommendations, platinum-based chemotherapy including cisplatin plus gemcitabine or the combination of methotrexate, vinblastine, doxorubicin, and cisplatin is expected to have similar efficacy as in bladder cancer.6 However, the vast majority of UC patients treated with these regimens develop progressive disease within 8 months, and survival is very short after the platinum-based chemotherapy failure.6,7,8 Many second-line regimens have been tested for advanced or metastatic UC in the past decade, but most have shown limited activity in patients with platinum-based chemotherapy refractory disease. Furthermore, chemotherapy-related toxicities often require treatment cessation, and may reduce survival in patients with postoperative renal dysfunction. Newer, safer, and more effective agents are urgently required.

We have recently reported that personalized peptide vaccination (PPV), in which peptides for vaccination were selected from 31 candidate peptides derived from various cancer antigens based on human leukocyte antigen (HLA) class I typing and pre-existing host immunity, was beneficial for advanced bladder cancer of UC refractory to platinum-based first-line chemotherapy in a randomized phase II trial.9 In that study, patients treated with PPV plus best-supportive care (BSC) showed a significantly longer overall survival (OS) compared with those of BSC alone (hazard ratio [HR], 0.58; 95% confidence interval [CI], 0.34–0.99, P = 0.049), with the median survival time (MST) being 7.9 months (95% CI, 3.5–12.0) in the PPV plus BSC group and 4.1 months (95% CI, 2.8–6.9) in the BSC group.

To address the applicability of PPV to patients with metastatic UTUC (mUTUC), we undertook a phase II clinical trial of PPV in patients with mUTUC refractory to platinum-based chemotherapy. We report the outcomes with respect to the safety of PPV, as well as its influence on host immunity and effect on OS compared with matched patients as historical controls.
Materials and Methods

Patients. Patients with pathologically confirmed mUTUC refractory to at least one platinum-based chemotherapy regimen were eligible for this study. Eligible patients were aged ≥20 years, and had ECOG performance status (PS) 0 or 1, life expectancy of at least 12 weeks, and adequate bone marrow function, hepatic function, and renal function. Other inclusion criteria were: positivity for HLA-A02, -A24, -A03 super types (A03, A11, A31, or A33), or -A26 type; IgG positivity for at least two of the 27 candidate peptides in pretreatment serum (Table S1). Exclusion criteria included pulmonary, cardiac, or other systemic diseases, acute infection, a history of severe allergy, pregnancy or breastfeeding, and other inappropriate conditions for enrollment as judged by clinicians.

All patients were given a detailed explanation of the protocol and provided informed consent before enrollment. The study protocol was approved by the Kurume University Ethics Committee (Kurume, Japan) and the trial was registered with the UMIN Clinical Trials Registry (UMIN000001854).

Study design and treatment. This was a single-arm, open-label phase II study that was designed to investigate the feasibility of PPV, immune response to PPV, and safety of PPV in patients with mUTUC. Twenty-seven candidate peptides, for which safety and immunologic effects have been confirmed in previous clinical studies, were prepared under Good Manufacturing Practice conditions by the Polypeptide Laboratories (San Diego, CA, USA) and American Peptide Company (Vista, CA, USA). Based on pre-existing host immunity, two to four HLA-matched peptides were selected for each patient by assessing the titers of specific IgG against each peptide, as described previously. The selected peptides (3 mg/each peptide) were given s.c. with incomplete Freund’s adjuvant (Montanide ISA51; Seppic, Paris, France) once a week for six consecutive weeks in the first cycle of vaccination followed by six times at 2- to 4-week intervals until unacceptable toxicity or withdrawal of consent in this study. Combination therapy with salvage chemotherapy was allowed during the vaccination for the patients who were expected to be tolerable.

Measurement of immune responses and laboratory markers. Peripheral blood (30 mL) was obtained from the patients before and after each cycle of six vaccinations. Plasma was separated by centrifugation and stored frozen until analysis, while PBMC were separated by density gradient centrifugation with Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden) and stored frozen until analysis. Specific humoral immune responses to the vaccine peptides were assessed by determining the peptide-specific IgG titers using a bead-based multiplex assay and the LumineX 200 system (Luminex, Austin, TX, USA). The cut-off values of IgG titers were set to 10 fluorescence intensity units in 100-times diluted samples. Cytotoxic T lymphocyte activity specific to the vaccinated peptide was evaluated by γ-interferon (IFN-γ) ELISPOT assay using PBMC, and analyzed with an ELISPOT reader (CTL-ImmunoSpot S5 Series; Cellular Technology, Shaker Heights, OH, USA). If total IgG titers to vaccinated peptides at six vaccinations were higher than those in the prevaccination plasma or more than 30 total spots to the corresponding peptide in the PBMC at six vaccinations was observed by IFN-γ ELISPOT assay, then these changes were considered to be positive immune responses.

The pre- and post-vaccination plasma level of interleukin-6 (IL-6) was examined by ELISA using kits from R&D Systems (Minneapolis, MN, USA), Life Technologies (Carlsbad, CA, USA), and eBioscience (Vienna, Austria), respectively. Bead-based multiplex assays and the LumineX 200 system were used to measure various cytokines, including IL-4, IL-13, IL-21, IFN-γ-induced protein 10, B-cell activating factor belonging to the tumor necrosis factor family (BAFF), and transforming growth factor-β.

Results

Patient characteristics. Between April 2009 and January 2016, 48 patients with mUTUC refractory to platinum-based chemotherapy were enrolled. Among them, 28 patients received both PPV and salvage chemotherapy based on the choice of the attending physicians (PPV plus salvage chemotherapy group), while the remaining 20 patients received PPV alone due to potential intolerance of chemotherapy (PPV group). Table 1 summarizes the demographics and baseline characteristics of these two groups. There were no significant differences in age, gender, performance status, clinical stage, or primary tumor site between the two groups. The majority of patients received more than two platinum-based chemotherapy regimens, with no significant between-group difference. Lung metastasis was more frequent in patients receiving both PPV and salvage chemotherapy than in patients given PPV alone (P = 0.0095), whereas liver metastasis (P = 0.1366) and lymph node metastasis (P = 0.0736) were less frequent. The percentage of patients with low hemoglobin (<10 g/dL) was lower in PPV alone group (P = 0.0238). In addition, the former group had fewer Bellmunt risk factors (PS, hemoglobin, and liver metastasis: three adverse risk factors that predict OS in patients with advanced UC refractory to platinum-based standard therapy) (P = 0.1083). Furthermore, the total of numbers 2 and 3 of Bellmunt risk factors was significantly lower in the former group (4/28, 14.3%)
compared to the latter group (9/20, 45%) ($P = 0.0247$). Moreover, the number of vaccinations was significantly higher in the former group (mean, 13; range, 5–29) than in the latter group (mean, 7; range, 1–23) ($P = 0.0049$). These differences could help to explain why only one patient from the PPV plus salvage chemotherapy group dropped out before the end of the first vaccination cycle (6th vaccination) because of disease progression and 12 patients dropped out before the end of the second vaccination cycle (12th vaccination), whereas 7 and 16 patients from the PPV group dropped out before the end of the first and second cycles, respectively. The regimens for salvage chemotherapy combined with PPV were gemcitabine ($n = 5$), gemcitabine and cisplatin ($n = 4$), tegafur-uracil and fluorouracil ($n = 14$), and others ($n = 11$).

**Adverse events.** Adverse events (AEs) are shown in Table 2. The most frequent AEs in all 48 patients were dermatologic reactions at the injection site (39/48, 81%), hypoalbuminemia (23/48, 48%), anemia (18/48; 38%), and lymphopenia (15/48; 31%). Among the serious AEs (SAEs), there was one grade 4 event (aspartate aminotransferase increased) and three grade 3 events (two cases of increased $\gamma$-glutamyl transpeptidase and one case of tumor pain, anemia, thrombocytopenia, lymphopenia, increased alanine aminotransferase, increased bilirubin, increased alkaline phosphatase, hyponatremia, and dyspnea). According to the independent safety evaluation committee, the SAEs were not directly associated with vaccination and were associated with other causes, such as combined chemotherapy, targeted therapies, or cancer progression. The incidence of anemia, increased alkaline phosphatase, and hypoalbuminemia was significantly higher in the PPV plus salvage chemotherapy group than in the PPV group.
Clinical responses. In the best clinical response evaluated by RECIST criteria, there was no complete response or partial response. Ten patients had stable disease and 38 patients had PD. Among 48 patients, 41 patients (85%) have died with a median follow-up of 6.6 months (95% CI, 7.9–16). The MST was 7.3 months (95% CI, 5.3–13.1) with a 1-year survival rate of 40% (Fig. 1a). Interestingly, the MST of the PPV plus salvage chemotherapy group was 13.0 months (95% CI, 5.7–17.5 months) and the 1-year survival rate was 51%, whereas the MST of the PPV group was only 4.5 months (95% CI, 1.7–10.1 months) and the 1-year survival rate was 25% (P = 0.080) (Fig. 1b).

Immune responses and OS. Peptide-specific IgG reactive to HLA-matched peptides were detectable in all 48 patients; the numbers of peptides used for the first cycle of vaccinations were four peptides in 42 patients, three peptides in four patients, and two peptides in two patients. Before the vaccination, peptide-specific IFN-γ spots were only detected in three of 43 patients (7%) tested, whereas responses to non-vaccinated control CEF peptides reactive to viral antigen were detectable in 30 of 43 patients (70%). Among 48 patients, 37 patients were analyzed for IgG and CTL responses at the end of six vaccinations. Immunoglobulin G and CTL responses specific to the vaccinated peptides were increased in 19 of 37 patients (51%) and in 17 of 37 patients (46%), respectively. Averages of IgG titers and IFN-γ spot numbers after six vaccinations were 14-fold (P = 0.015) and 140-fold (P < 0.001) higher than those at pre-vaccination, respectively, when those levels at pre-vaccination were set as 1.0.

We also performed an OS subgroup analysis based on groups stratified by the status of positive immune responses. To reduce the biases in the statistical analysis for comparisons of OS between immune response-positive and -negative groups, we used the landmark time analysis in which the survival after six vaccinations was evaluated by immune response status after six vaccinations. In the landmark time analysis,
the MST for patients with positive and negative CTL responses were 11.6 months (95% CI, 4.4–18.1) and 6 months (95% CI, 1.1–11.9), respectively. Patients with positive CTL responses showed a significantly longer survival than patients with negative CTL responses (HR, 0.37; 95% CI, 0.16–0.85; \( P = 0.019 \)) (Fig. 2a). The MST for patients with positive and negative IgG responses were 8.9 months (95% CI, 4.4–18.1) and 5.8 months (95% CI, 3.2–15.3). In addition, patients with both positive CTL and IgG responses showed significantly longer survival than those with positive CTL alone, positive IgG alone, or negative CTL and IgG (HR, 0.32; 95% CI, 0.12–0.74; \( P = 0.007 \)) (Fig. 2b).

**Relationship between baseline clinical findings or laboratory data and OS.** To identify baseline factors significantly associated with OS from among prevaccination clinical findings or laboratory data, the Cox proportional hazards model was used. As shown in Table 3, univariate analysis of prevaccination findings showed that the number of Bellmunt risk factors (\( P = 0.0182 \)), the number of previous chemotherapy regimens (\( P = 0.0480 \)), albumin (\( P = 0.0470 \)), BAFF (\( P = 0.0003 \)), haptoglobin (\( P = 0.0130 \)), and IL-6 (\( P = 0.0359 \)) were significant prognostic factors for OS. None of the other factors examined were significantly correlated with OS. Multivariate Cox regression analysis was undertaken to evaluate the influence of each factor that showed a significant association with OS in the univariate analysis with \( P \)-value <0.1. As indicated in Table 3, a lower number of Bellmunt risk factors (HR, 0.379; 95% CI, 0.151–0.895; \( P = 0.0265 \)) and a lower BAFF level in prevaccination plasma (HR, 0.249; 95% CI, 0.094–0.616; \( P = 0.0024 \)) were significantly predictive of favorable OS. Relationships between the increase in peptide-specific CTL responses after PPV and other potential prognostic factors, including prevaccination number of chemotherapy regimens, number of Bellmunt risk factors, and albumin, BAFF, haptoglobin, IFN-\( \gamma \)-induced protein 10, and IL-6 levels, were examined by multivariate logistic regression analysis (Table 4). The level of BAFF and haptoglobin were predictive of the increase in peptide-specific CTL responses (BAFF: OR, 0.088; 95% CI, 0.013–0.612; \( P = 0.014 \); haptoglobin: OR, 15.513; 95% CI, 1.455 to 165.363; \( P = 0.023 \)), whereas other factors were not predictive.

**Discussion**
As expected, the most frequent AEs in all 48 patients were dermatologic reactions at the injection site (39/48, 81%), but the SAEs were not directly associated with vaccination and
were associated with other causes, such as combined chemotherapy, targeted therapies, or cancer progression, in agreement with the our previous reports on PPV.\(^{9-13}\) However, the incidence of anemia, increased alkaline phosphatase, and hypoalbuminemia were significantly higher in the PPV plus salvage chemotherapy group than in the PPV group. This could be mainly due to the combined chemotherapy. Higher fever was rarely observed during the PPV treatment in UTUC patients.

We have shown that survival in UTUC patients with positive CTL responses is significantly longer than in patients with negative CTL responses. Patients with positive IgG responses showed a trend of longer survival (data not shown). Collectively, the patients with both positive CTL and IgG responses showed significantly longer survival than those with positive CTL alone, positive IgG alone, or negative CTL and IgG \((P = 0.037)\). We also analyzed the relationship between PPV-induced CTL responses and OS by multivariate Cox regression model. Several prevaccination factors were also provided as the control. However, the positive CTL response was not significantly prognostic factor for OS, although it was the case for BAFF (Table S2).

We have been considering the causal relationship between peptide-specific CTL responses and longer survival benefit in patients who receive PPV. This causal relationship has been repeatedly reported in our published work on PPV for various advanced cancers,\(^{14-16}\) in agreement with the results in UTUC shown in this study.

We previously reported IgG boosting for non-vaccinated peptides in advanced ovarian cancer patients, in which the IgG boosting (so-called antigen spreading) well correlated with favorable clinical benefits.\(^{17}\) We then examined the frequency of antigen spreading in UTUC patients treated with PPV, and found that it was observed in 19 of 40 tested patients. The MST of these 19 patients was somewhat longer than that of the remaining 21 patients without antigen spreading (13.3 months vs 7.3 months; \(P = 0.310\)).

In this phase II study for 48 patients with mUTUC that progressed after platinum-based chemotherapy, the MST was 7.3 months (95% CI, 5.3–13.1) with 13.0 months for patients receiving combined salvage chemotherapy (95% CI, 5.7–17.5) and 4.5 months for patients receiving PPV alone (95% CI, 1.7–10.1) \((P = 0.080)\). These differences in survival could have been partly due to the differences in Bellmunt risk

### Table 4. Multivariate logistic analysis for predicting peptide-specific CTL after personalized peptide vaccination in patients with metastatic upper tract urothelial carcinoma

| Factor                        | OR (95% CI)     | P-value |
|-------------------------------|-----------------|---------|
| Number of previous chemotherapy regimens | 1.755 (0.155–19.881) | 0.649   |
| Number of Bellmunt risk factors | 0.550 (0.050–6.090) | 0.626   |
| Albumin | 1.171 (0.175–7.842) | 0.871   |
| BAFF | 0.088 (0.013–0.612) | 0.014   |
| Haptoglobin | 15.513 (1.455–165.363) | 0.023   |
| IP-10 | 1.071 (0.125–9.169) | 0.950   |
| IL-6 | 0.438 (0.066–2.928) | 0.395   |

BAFF, B-cell activating factor belonging to the tumor necrosis factor family; CI, confidence interval; IL, interleukin; IP-10, interferon-γ-induced protein 10; OR, odds ratio.

### Table 3. Univariate and multivariate analyses for overall survival, with prevaccination clinical findings or laboratory data, in patients with metastatic upper tract urothelial carcinoma treated with personalized peptide vaccination

| Factor                        | Univariate analysis   | Multivariate analysis |
|-------------------------------|-----------------------|-----------------------|
|                               | HR (95% CI)           | P-value               | HR (95% CI)           | P-value               |
| Age                           | 1.698 (0.881–3.263)   | 0.1127                | 0.781 (0.327–1.714)   | 0.5501                |
| Number of previous chemotherapy regimens | 0.497 (0.231–0.994)   | 0.0480                | 0.379 (0.151–0.895)   | 0.0265                |
| Lymphocytes                  | 1.523 (0.816–2.816)   | 0.1838                | 1.523 (0.776–2.981)   | 0.2192                |
| Number of Bellmunt risk factors | 0.429 (0.194–0.871)   | 0.0182                | 0.249 (0.094–0.616)   | 0.0024                |
| Albumin                      | 1.877 (1.009–3.504)   | 0.0470                | 1.966                  | 0.9011                |
| BAFF                         | 0.282 (0.138–0.560)   | 0.0003                | 0.249 (0.094–0.616)   | 0.0024                |
| TGF                          | 0.684 (0.363–1.279)   | 0.2329                | 0.388 (0.108–1.331)   | 0.1327                |
| Haptoglobin                  | 0.449 (0.236–0.843)   | 0.0130                | 0.577 (0.235–1.418)   | 0.2282                |
| IL-24                        | 1.041 (0.555–1.966)   | 0.9011                | 1.048 (0.539–1.967)   | 0.8871                |
| IP-10                        | 0.564 (0.293–1.072)   | 0.0802                | 1.015 (0.542–1.902)   | 0.9630                |
| IL-13                        | 0.828 (0.436–1.559)   | 0.5569                | 1.057 (0.555–2.017)   | 0.8332                |
| IL-10                        | 0.665 (0.336–1.261)   | 0.2143                | 1.015 (0.542–1.902)   | 0.9630                |
| IL-6                         | 0.506 (0.268–0.956)   | 0.0359                | 0.506 (0.268–0.956)   | 0.0359                |
| GM-CSF                       | 0.968 (0.512–1.807)   | 0.9199                | 0.577 (0.235–1.418)   | 0.2282                |
| IL-5                         | 1.048 (0.539–1.967)   | 0.8871                | 1.057 (0.555–2.017)   | 0.8332                |
| IFN-γ                         | 1.071 (0.555–2.017)   | 0.8332                | 1.071 (0.555–2.017)   | 0.8332                |
| TNF-α                        | 1.015 (0.542–1.902)   | 0.9630                | 1.015 (0.542–1.902)   | 0.9630                |
| IL-2                         | 0.597 (0.305–1.141)   | 0.1187                | 0.597 (0.305–1.141)   | 0.1187                |
| IL-4                         | 0.904 (0.473–1.693)   | 0.7536                | 0.904 (0.473–1.693)   | 0.7536                |
| IL-8                         | 0.667 (0.355–1.247)   | 0.2039                | 0.667 (0.355–1.247)   | 0.2039                |

BAFF, B-cell activating factor belonging to the tumor necrosis factor family; CI, confidence interval; GM-CSF, granulocyte/macrophage colony-stimulating factor; HR, hazard ratio; IFN-γ, γ-interferon; IL, interleukin; IP-10, IFN-γ-induced protein 10; TGF, transforming growth factor; TNF-α, tumor necrosis factor-α.
PPV in upper tract urothelial cancer

Factors, as the PPV plus salvage chemotherapy group had a significantly smaller number of risk factors than the PPV group (Table 1). This could also be largely responsible for the differences in early dropout from the PPV trial. Namely, one patient from the PPV plus salvage chemotherapy group (n = 28) dropped out before the end of the first cycle and 12 dropped out before the end of the second cycle because of disease progression, whereas the corresponding numbers were 7 and 9 in the PPV group (n = 20). Only one of the 13 patients with two or three Bellmunt risk factors completed the second vaccination cycle, suggesting a close relation between early dropout and a higher number of risk factors.

In addition, MST of 48 patients treated with PPV after the start of first-line chemotherapy was significantly longer than the control patients who matched to Bellmunt risk factors in our institution (27.1 months vs 11.2 months). Of note, the MST in patients with UC after the start of first-line chemotherapy has been reported to be 12–15 months. Personalized immunotherapies were vaccinated without SAEs; immune-related AEs with PPV were mostly dermatologic reactions at the injection site with grade 1 or 2 severity. The safety profile of PPV is important, considering that patients with refractory mUTUC are generally older and have poor PS, impaired renal function, and multiple coexisting conditions. These adverse events might have impeded PPV for platinum-based chemotherapy refractory patients with mUTUC has the potential to prolong survival with a high proportion of patients maintaining a quality of life when combined with salvage chemotherapy.

Immunotherapy for the treatment of cancer has made significant progress over the past two decades. There is remarkable progress in cancer immunotherapy with immune checkpoint inhibitors, such as anti-CTLA antigen 4, anti-programmed death-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) antibody for advanced stages of cancers, including melanoma, lung cancer, renal cell carcinoma, ovarian cancer, and bladder cancer. Checkpoint inhibition involves targeting T-cell regulatory pathways to reduce inhibitory signaling and promote T-cell activation and enhanced antitumor activity. After the long void of no advances for advanced UC, the FDA approved atezolizumab, a PD-L1 antibody, for use in advanced UC patients who have progressed to platinum-based chemotherapy, in May 2016. This approval was based on data from a single-arm, multicenter, phase II study with 315 patients that showed significant objective response rate and durability of responses. The primary outcome of ORR was obtained in 15% of patients, with 5% obtaining a complete response, and presence of PD-L1+ tumor-infiltrating lymphocytes was a favorable predictive biomarker for this treatment. Moreover, an anti-PD-1 antibody, pembrolizumab, has been approved as the second-line therapy for advanced UC based on the results from an open-label, international, phase III trial for patients with advanced UC undertaken by J. Bellmunt and the KEYNOTE-045 investigators (MST, 10.3 months; 95% CI, 8.0–11.8 [pembrolizumab group] vs 7.4 months; 95% CI, 6.1–8.3 [chemotherapy group] (HR, 0.73; 95% CI, 0.59–0.91; P = 0.002))

Several novel immunotherapy agents with unique mechanisms of action are currently being explored. One of them is PPV treatment, and we had previously reported that PPV induced quicker and stronger immune responses with certain clinical benefits compared to the conventional peptide vaccine with rare clinical benefits. The quicker and stronger PPV-induced immune responses could be explained by its ability to induce rapid infiltration of CD45RO+ activated/memory lymphocytes into tumor sites, and PPV thereafter recruited CD45RA+ effector T cells into tumor sites to efficiently eliminate tumor cells. Our previous phase I study of PPV in patients with advanced bladder cancer who failed treatment with methotrexate, vinblastine, doxorubicin, and cisplatin, showed some promising data. In that trial, 10 patients received PPV treatment in the second-line setting. The disease control rate was 40% and the median OS time was 8.9 months with good immune response and minimal toxicity. Subsequently, we undertook a randomized phase II study of PPV for patients with advanced bladder cancer who failed platinum-based chemotherapy, comparing BSC. Patients treated with PPV plus BSC showed a significantly longer OS compared with those who received BSC alone, with an MST of 7.9 months in the PPV plus BSC group and 4.1 months in the BSC group. In this study, the disease control rate was obtained in 21% (10/48) of patients. Personalized peptide vaccination also resulted in successful boosting of CTLs, with longer survival after the start of first-line chemotherapy than reported historical controls. These data suggest that PPV is an option in platinum-based chemotherapy refractory patients with mUTUC, as a second-line treatment.
Acknowledgments

This study was supported by the Japan Society for the Promotion of Science (KAKENHI Grant No. JP15K10614), and a research grant from the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct) and the Regional Innovation Cluster Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Sendai Kosei Hospital, Japan.

References

1. Bellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28: 1850–5.
2. Sharlat SF, Favaretto RL, Gupta A et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 2011; 29: 481–6.
3. Lughezzani G, Sun M, Perrotte P et al. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database. Urology 2010; 75: 321–7.
4. Margulis V, Sharlat SF, Matin SF et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115: 1224–33.
5. Lughezzani G, Ieldres C, Isham H et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology 2010; 75: 118–24.
6. Roupé M, Zigeuner R, Palou J et al. [European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract]. Actas Urol Esp 2012; 36: 2–14.
7. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–86.
8. Hsieh MC, Chiang PH, Rau KM, Chen YY, Su YL, Huang CH. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy. Urol Oncol 2015; 33: 495.e9–e14.
9. Noguchi M, Matsumoto K, Uemura H, Arai G, Eto M, Naito S, et al. An open-label, randomized phase II trial of personalized peptide vaccination in patients with bladder cancer that progressed after platinum-based chemotherapy. Clin Cancer Res 2016; 22: 54–60.
10. Sasada T, Yamada A, Noguchi M, Itoh K. Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem 2014; 21: 2332–45.
11. Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother 2013; 62: 919–29.
12. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710–9.
13. Matsumoto K, Noguchi M, Satoh T et al. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, Adriamycin and cisplatin. BJU Int 2011; 108: 831–8.
14. Tajima N, Yamakawa R, Mine T et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005; 11: 5900–11.
15. Noguchi M, Mine T, Komatsu N et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 2010; 10: 1266–79.
16. Kibe S, Yutani S, Motoyaama S et al. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer. Cancer Immunol Res 2014; 2: 1154–62.
17. Kawano K, Tsuda N, Sasada K et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacol Immunotoxicol 2014; 36(3): 224–36.
18. Seron E, Machiels JP, Molecular biology and targeted therapies for urothelial carcinoma. Cancer Treat Rev 2015; 41: 341–53.
19. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–54.
20. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455–65.
21. Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558–62.
22. Bellmunt J, de Wit R, Vaughn DJ et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376: 1015–26.
23. Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicenter, phase 2 trial. Lancet 2016; 387: 1909–20.
24. Noguchi M, Yao A, Harada M et al. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 2007; 67: 933–42.
25. Batten M, Groom J, Cachero TG et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000; 192: 1453–66.
26. Thompson JS, Bixler SA, Quan F et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293: 2106–11.

Disclosure Statement

Masanori Noguchi is an advisory board consultant of Green Peptide Co., Ltd. Kyogo Itoh has stock ownership of Green Peptide Co., Ltd. and received research funding from Taiho Pharmaceutical Company. Takuto Yamashita is an employee of Green Peptide Co., Ltd. The other authors have no conflict of interest.

Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article:

Fig. S1. B-cell activating factor belonging to the tumor necrosis factor family (BAFF), haptoglobin, and interleukin (IL)-6 scores in each CTL and IgG response in patients with metastatic upper tract urothelial carcinoma who received personalized peptide vaccination.

Table S1. Peptide candidates for personalized peptide vaccination.

Table S2. Multivariate analysis for overall survival (OS) with post-vaccination CTL responses in patients with metastatic upper tract urothelial carcinoma who received personalized peptide vaccination.